Albert David Full Year 2025 Earnings: EPS: ₹30.14 (vs ₹132 in FY 2024)
Albert David (NSE:ALBERTDAVD) Full Year 2025 Results
Key Financial Results
- Revenue: ₹3.75b (up 3.6% from FY 2024).
- Net income: ₹172.0m (down 77% from FY 2024).
- Profit margin: 4.6% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses.
- EPS: ₹30.14 (down from ₹132 in FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Albert David shares are up 2.3% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 4 warning signs for Albert David (1 doesn't sit too well with us!) that you need to be mindful of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:ALBERTDAVD
Albert David
Manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India.
Established dividend payer with adequate balance sheet.
Market Insights
Community Narratives

